Business Context and Reporting Period
This Form 8-K, filed on January 9, 2017, reports a material event occurring on January 6, 2017. Mast Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger with Savara Inc., a privately-held Delaware corporation focused on rare respiratory diseases. Upon consummation, Mast Therapeutics will change its name to Savara Inc.
Key Financial Metrics and Transaction Terms
The filing details a reverse merger structure rather than providing standard operating financial metrics (revenue, profit, cash flow) for the reporting period.
- Ownership Structure: Post-merger, former Savara securityholders are expected to own approximately 76% of the aggregate shares, while existing Mast Therapeutics stockholders will own approximately 24%.
- Exchange Ratio Adjustment: The ratio may be adjusted downward for existing Mast stockholders if the Company's net cash at closing is less than zero dollars.
- Termination Fees: The Company may be required to pay Savara $1.8 million, or Savara may be required to pay the Company $2.5 million, depending on the circumstances of termination.
- Capitalization: The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Material Changes and Governance
The transaction constitutes a change in control of the registrant. Key governance changes include:
- Board Composition: The new Board will consist of seven members: five current Savara directors and two independent directors designated by the Company (expected to be current Mast directors).
- Executive Leadership: Robert Neville (Savara CEO) will become the Company's CEO, and David Lowrance (Savara CFO) will become the Company's CFO.
- Stock Split: The Company intends to seek stockholder approval for a reverse stock split to meet NYSE MKT minimum trading price requirements.
- Lock-Up Agreements: Officers and directors of both companies have agreed not to sell shares for a period following the merger, with restrictions releasing in thirds at 6, 8, and 10 months post-closing.
- Verify the final exchange ratio and net cash position at closing to confirm the 76%/24% ownership split.
- Review the upcoming Form S-4 (joint proxy statement/prospectus) for detailed financial data on Savara Inc.
- Confirm the specific ratio of the proposed reverse stock split once approved by stockholders.
- Monitor the status of stockholder approvals required from both entities to close the transaction.
- Assess the impact of the termination fee provisions ($1.8M or $2.5M) on potential deal failure scenarios.
Outlook, Risks, and Contingencies
The consummation of the Merger is subject to several conditions, including stockholder approval from both Mast Therapeutics and Savara. The filing notes that representations and warranties are qualified by confidential disclosure schedules and should not be relied upon as characterizations of actual facts without reviewing the full Merger Agreement. The Company has not independently verified the information in Savara's corporate presentation (Exhibit 99.2).